ClinicalTrials.gg
Sign In
RecruitingNCT03778944Updated Jan 12, 2026

Enhancing Renal Graft Function During Donor Anesthesia

An interventional study of Mannitol infusion and Dopamine infusion in Renal Failure Chronic, Transplant;Failure,Kidney and Anesthesia, sponsored by Nazmy Edward Seif. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Nazmy Edward Seif · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Dec 2018; still recruiting 7 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Renal transplantation is now recognized as the treatment of choice for patients with end-stage renal disease. An optimum anesthetic regimen should enhance the function and perfusion of the transplanted kidney. The aim of this study is to assess \& compare the effectiveness of 3 different modalities in this respect: Mannitol, Dopamine and adequate hydration.

02

Conditions studied

  • Renal Failure Chronic
  • Transplant;Failure,Kidney
  • Anesthesia

Keywords

  • Mannitol
  • Dopamine
  • Perfusion
  • Renal graft donor
  • Anesthesia
03

In context

Renal Insufficiency, Chronic

3,090 studies on the registry are indexed under Renal Insufficiency, Chronic; 698 are open to participants now.

This study's planned enrollment of 60 is below the median of 73 across 2,157 interventional studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

Nazmy Edward Seif is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • end-stage renal disease, for living-donor kidney transplantation

Exclusion criteria

Exclusion Criteria:

  • severe cardiac or hepatic dysfunction
  • coagulopathy
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    M group

    Mannitol infusion

    Procedure: Mannitol infusion

  • Active comparator
    D group

    Dopamine infusion

    Procedure: Dopamine infusion

  • Active comparator
    C group

    Adequate hydration

    Procedure: Adequate hydration

Interventions

  • ProcedureMannitol infusion

    Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.

  • ProcedureDopamine infusion

    Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.

  • ProcedureAdequate hydration

    Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.

06

What researchers measure

Primary outcomes

  1. Post-operative creatinine clearance

    Post-operative creatinine clearance level of the transplanted kidney graft is measured in ml/min

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Dec 2026, 96 months after the start.

Of 576 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 96 months is above that.

Counting every sponsor, half of 616 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2018
First posted
Dec 19, 2018
StartActual
Dec 20, 2018
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03778944
Lead sponsor
Nazmy Edward Seif
Responsible party
Nazmy Edward Seif (Clinical Professor, Cairo University) — Sponsor-investigator
First posted
Dec 19, 2018
Start date
Dec 20, 2018
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 12, 2026

Study contacts

Nazmy E Seif, MD
Contact
drnazmyseif@yahoo.com
01227400808 ext. +2
Ahmed M Elbadawy, MD
Contact
elbadawyahmed89@yahoo.com
01064249076 ext. +2
Nazmy E Seif, MD
study chair · Kasr Al-Ainy Hospital, Cairo University
Ahmed M Elbadawy, MD
study director · Kasr Al-Ainy Hospital, Cairo University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Renal Insufficiency, Chronic →

Other studies from this sponsor

Nazmy Edward Seif

Start the discussion